Please login to the form below

Not currently logged in
Email:
Password:

Kite Pharma

This page shows the latest Kite Pharma news and features for those working in and with pharma, biotech and healthcare.

FDA expecting boom in cell and gene therapies

FDA expecting boom in cell and gene therapies

for cancer from Novartis and Gilead/Kite Pharma, and there are plenty more in mid- to late-stage development.

Latest news

  • Roche's O’Day swaps big pharma for big biotech Roche's O’Day swaps big pharma for big biotech

    Move to Gilead enforces reshuffle at neighbours Genentech. Gilead has selected Daniel O'Day, the current chief executive of Roche's pharma business, to take over as its CEO from 1 ... Among Gilead's moves is a shift into immuno-oncology via the

  • Allogene raises $324m from record-breaking IPO for off-the shelf CAR-Ts Allogene raises $324m from record-breaking IPO for off-the shelf CAR-Ts

    The new biotech's executive chairman Arie Belldegrun and CEO David Cheng brought cell therapy specialist Kite Pharma from a start-up to an almost $12bn buyout, and investors are confident ... Kite was sold on to Gilead Sciences, along with FDA-approved

  • Novartis’ CAR-T Kymriah gets green light in England Novartis’ CAR-T Kymriah gets green light in England

    The rapid agreement on Kymriah is in stark contrast to NICE’s speedy rejection in draft guidance of Gilead/Kite Pharma’s rival CAR-T Yescarta (axicabtagene ciloleucel), which was approved

  • It’s a no for Yescarta, says NICE on heels of EU approval It’s a no for Yescarta, says NICE on heels of EU approval

    Gilead gets rapid knock-back from cost effectiveness watchdog. NICE has lost no time in firing a broadside across the bows of Gilead/Kite after the EU approval of its ... for use in the NHS in England at the cost per patient set by Kite Pharma,” said

  • J&J moves quickly ahead with trials of myeloma CAR-T J&J moves quickly ahead with trials of myeloma CAR-T

    J&J is going up against some well-positioned competitors in the anti-BCMA CAR-T category, notably Celgene and Bluebird Bio with bb2121, Celgene and Juno with and Kite ... Gilead Sciences’ KITE-585, both of which are on the agenda of this year’s ASCO

More from news
Approximately 15 fully matching, plus 30 partially matching documents found.

Latest Intelligence

  • The good, the bad and the ugly The good, the bad and the ugly

    The company hopes its $12bn acquisition of Kite Pharma (August 2017) will help it steal a march on the lucrative CAR-T market through its treatment for advanced lymphoma. ... The data this article was based on is available in full online:

  • Pharma deals continue to slide Pharma deals continue to slide

    Given big pharma’s reluctance to spend on M&A it is perhaps surprising that this month Gilead has announced the $11.9bn acquisition of Kite Pharma. ... Licensing  . The most common licensing deal is big pharma licensing in from biotech.

  • Deal Watch January 2017 Deal Watch January 2017

    Kite Pharma. Daiichi Sankyo. Licence. Cellular cancer therapy axicabtagene ciloleucel (KTE-C19). ... 160. Kite Pharma. Fosun Pharma. Formation of a JV. Autologous T-cell therapies in cancer.

  • Deal Watch November 2016 Deal Watch November 2016

    As Juno wrestles with bad publicity and a depressed share price, Novartis and Kite Pharma, also active in the CAR T cell space, presented promising data at the ASH meeting for ... licence. 115.5. Medivir | BioPhausia/ Karo Pharma. business with 13

  • Deal Watch June 2016 Deal Watch June 2016

    licence. 770. Teva and Allergan/ Mayne Pharma. US generic portfolio of 37 approved and 5 FDA filed products. ... licence. 80. Cell Design Labs/ Kite Pharma. 'On/off switch' technology to regulate activity of engineered CAR T-cells for AML, certain B-cell

More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest appointments

More from appointments
Approximately 4 fully matching, plus 5 partially matching documents found.

Latest from PMHub

  • How do you define a biotech company?

    Johnson &Johnson and Pfizer are two of the largest pharma companies in the world by revenue but both have numerous biological therapies. ... This approach is particularly apparent in some of the recent examples of technology pioneered by biotech

  • Random42 Scientific Communication

    Collegium Pharmaceutical. CSL Behring. Dainippon Sumitomo Pharma. Daiichi-Sankyo. DePuy Synthes. DBV Technologies . ... Janssen. Keryx Biopharmaceuticals. KindredBio. Kite Pharma. Lifes2Good. MedImmune. Merck. MSD. Merck Serono.

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health

Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...

Latest intelligence

The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
Escaping the spin cycle of sub-optimal launch
...

Infographics